Alexion Pharmaceuticals Inc ALXN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/05/21 EST
150.10UNCH (UNCH)
Volume
89,885
Close
150.10quote price arrow up+1.64 (+1.10%)
Volume
2,963,668
52 week range
72.67 - 162.60

...

Loading . . .

KEY STATS

  • Open149.20
  • Day High150.56
  • Day Low148.18
  • Prev Close148.46
  • 52 Week High162.60
  • 52 Week High Date01/26/21
  • 52 Week Low72.67
  • 52 Week Low Date03/16/20
  • Market Cap32.999B
  • Shares Out219.85M
  • 10 Day Average Volume2.92M
  • Dividend-
  • Dividend Yield-
  • Beta1.28
  • 1 Year % Change63.19

RATIOS/PROFITABILITY

  • EPS (TTM)2.69
  • P/E (TTM)55.72
  • Fwd P/E (NTM)12.06
  • EBITDA (MRQ)3.128B
  • ROE (MRQ)5.26%
  • Revenue (MRQ)6.07B
  • Gross Margin (MRQ)90.88%
  • Net Margin (MRQ)9.94%
  • Debt To Equity (MRQ)21.99%

EVENTS

  • Earnings Date05/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Alexion Pharmaceuticals Inc News

Latest ALXN News From Our Partners

QUOTE FINDER

Profile

MORE
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and...
David Brennan
Chairman
Ludwig Hantson Ph.D.
Chief Executive Officer
Aradhana Sarin M.D.
Chief Financial Officer
Brian Goff
Executive Vice President
John Orloff
Executive Vice President
Address
121 Seaport Blvd
Boston, MA
02210-2050
United States